Press Releases

and/or
572 News Releases found
Researchers Find Drug Combination Reduces Recurrence Risk in Patients with HER2-Positive Early Breast Cancer

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.
Dr. Monica Morrow
Study Finds Rate of Mastectomies Decreases with Adoption of Breast Tumor Margin Guidelines: What This Means in the Overtreatment Debate for Breast Cancer

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.
Dr. Mark E. Robson, MD
Phase III Trial of PARP Inhibitor Shows First Evidence of Improved Outcomes in Breast Cancer

Increased progression-free survival and a better quality of life were seen in HER2-negative metastatic breast cancer patients with a BRCA mutation who were treated with olaparib versus a single-agent chemotherapy.
Dr. Ethan Basch, MD. Photo Credit: Brian Strickland/UNC Lineberger Comprehensive Cancer Center
Real-Time, Patient-Reported Symptom Monitoring Demonstrates an Overall Survival Benefit

Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the annual meeting of the American Society of Clinical Oncology. Data showed that systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes (PROs) improved overall survival.
Novel Sequencing Approach Seeks to Detect Cancer’s Genomic Alterations

Findings Could Inform the Development of a Blood Test for Early Cancer Detection
Dr. David Hyman, MD
Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

Breakthrough findings illustrate the promise of precision oncology and signify a paradigm shift in drug development. Interim data from three trials show a 76 percent confirmed overall response rate in patients treated with the TRK inhibitor.
MSK Leadership attend the Topping Off of The David H. Koch Center for Cancer Care
Memorial Sloan Kettering Cancer Center Holds “Topping Off” Ceremony for David H. Koch Center for Cancer Care

Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center for Cancer Care. The 750,000-square-foot, 23-story outpatient cancer center on East 74th Street and FDR Drive is made possible by a landmark gift of $150 million from Mr. Koch, the largest single gift in the history of the institution.
Landmark Analysis from Memorial Sloan Kettering Reveals Genomic Tumor Sequence of More Than 10,000 Cancer Patients Using MSK-IMPACT™

Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD, Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical genomic sequencing by MSK-IMPACT™, a powerful diagnostic test developed at MSK to provide detailed genetic information about a patient’s cancer.
World-Renowned Medical Oncologist Luis Diaz, MD, Named Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center

Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and leader in the field of clinical oncology, Dr. Diaz most recently served as an associate professor of oncology at the Johns Hopkins University School of Medicine. Dr. Diaz formally assumes the role as David Spriggs, MD, steps down after nearly 13 years.
Jae Park, MD
MSK Expertise on Immunotherapy Highlighted in American Association for Cancer Research Annual Meeting Press Program

Jae Park, MD, a hematologic oncologist and assistant attending physician at MSK, will present findings about the durability of CAR T cell therapy response in patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) at the American Association for Cancer Research (AACR) Annual Meeting. This research has been selected to be featured in the meeting’s press program.